VALUE: After Hours (S08 E02): 2026–2030 Patent Cliff: Biggest in Pharma History | The Acquirer's Multiple®

VALUE: After Hours (S08 E02): 2026–2030 Patent Cliff: Biggest in Pharma History | The Acquirer's Multiple®

During their recent episode, Taylor, Carlisle, and Andrew Summers discussed 2026–2030 Patent Cliff: Biggest in Pharma History. Here’s an excerpt from the episode: Now, the one thing that I would point out, and I think this is incredibly important, and it’s more of a macro-observation. But we’re sitting here today in 2026. Between 2026 and 2030, there is a pretty significant patent expiration wave affecting large-cap pharmaceutical companies. In …

Life sciences M&A hit $240B in 2025 as Big Pharma preps for patent cliffs

Global life sciences dealmaking jumped in 2025, with M&A investment hitting $240 billion. That’s an 81% jump from $130 billion in the prior year. One factor driving the convergence is patent expirations, which are pressuring the growth outlook. For instance, Merck faces Keytruda patent protections expiring around 2028 in the U.S. Meanwhile, AbbVie has already… The post Life sciences M&A hit $240B in 2025 as Big Pharma preps for patent cliffs app…